In this episode, Naturopath Fiona Chin sits down with peptide expert Dr Grace Liu for a deep dive into the science and clinical applications of KPV (Lysine-Proline-Valine), a naturally occurring tripeptide derived from alpha-MSH with remarkable anti-inflammatory, antimicrobial and gut-healing properties.
Together, they explore how KPV works to regulate inflammation through NF-κB inhibition, reduce pro-inflammatory cytokines, support the gut barrier, influence the microbiome, and potentially assist in conditions ranging from inflammatory bowel disease and Candida overgrowth to autoimmune disease, psoriasis, eczema, mould illness and Long COVID.
They also discuss: The origins of KPV as an endogenous antimicrobial peptide Why KPV is different from antibiotics and steroids KPV’s effects on Candida, Staphylococcus and Streptococcus Histamine, mast cell activation and when KPV should be used cautiously Practical dosing strategies (oral, nasal, subcutaneous and topical) Skin applications, including psoriasis, eczema, wound healing and dermatology M1 to M2 macrophage polarisation and immune regulation How KPV fits into broader peptide and bioregulator protocols Clinical pearls from real patient cases Whether you’re a practitioner, biohacker or someone interested in advanced peptide therapies, this conversation offers a practical, evidence-informed look at one of the most promising peptides in regenerative medicine.
Time Stamps:
00:00 Introduction
02:15 What is KPV?
03:00 Origins of KPV & Alpha-MSH
05:20 Is KPV a Bioregulator?
10:10 How KPV Reduces Inflammation
12:45 Histamine & Mast Cell Considerations
14:00 GLP-1, Mast Cells & Gut Health
18:05 KPV for IBD & Leaky Gut
19:45 Mould, Candida & Microbiome Support
22:45 Autoimmune Disease & Macrophage Polarisation
25:10 Clinical Applications & Case Studies
30:20 Dosing: Nasal, Oral, Sub-Q & Topical
32:45 Hair Loss, Skin & Autoimmunity
36:20 Gut Healing & Future Peptide Therapies
40:20 KPV for Skin Repair & Wound Healing
44:10 Patient Results & HRV Improvements
46:20 KPV for Hair Growth & Long COVID
49:30 Final Clinical Pearls











